BTIG Research has recently resumed Akebia Therapeutics Inc (AKBA) stock to Buy rating, as announced on November 29, 2023, according to Finviz. Earlier, on August 28, 2023, H.C. Wainwright had raised the stock from a Neutral to Buy, setting a price target of $3.75. Piper Sandler also raised Overweight rating with a price target of $4. Additionally, Piper Sandler reduced Neutral rating on March 31, 2022, with a target price of $2. Needham analysts, in their report published on March 31, 2022, also reduced Hold rating for Akebia Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Akebia Therapeutics Inc (AKBA) Stock Trading Recap
On Tuesday, Akebia Therapeutics Inc (AKBA) stock saw a decline, ending the day at $1.28 which represents a decrease of $-0.04 or -3.03% from the prior close of $1.32. The stock opened at $1.3 and touched a low of $1.24 during the day, reaching a high of $1.32. The volume of shares traded was 1.83 million falling short of the average volume of 2.02 million.
AKBA Stock Performance and Moving Averages
In recent trading, Akebia Therapeutics Inc (AKBA) stock price has shown some volatility, fluctuating -5.19% over the last five trades and -17.42% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -18.99%, and it has gained 33.33% in the previous three months. Currently, AKBA is trading at -7.23%, -7.55%, and -6.93% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, AKBA, a Healthcare sector stock, is trading -48.39% below its 52-week high but remains 64.08% above its 52-week low. The Average True Range (ATR) (14 days) of 0.07 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Akebia Therapeutics Inc’s Profitability and Valuation Ratios
Akebia Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -20.11% and a profit margin of -23.18%, with a gross margin of -18.99%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Akebia Therapeutics Inc’s market capitalization stands at $269.17 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 1.54, reflecting the market’s valuation of the company’s sales.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 5.03% of Akebia Therapeutics Inc (AKBA)’s shares, while financial institutions hold 24.16%.
